Scholarlink

Background and Aims <p>We evaluated whether age modifies treatment efficacy and safety of advanced therapies in patients with moderate-to-severe ulcerative colitis (UC).</p> Methods <p>Through an individual patient-level data (IPD) meta-analysis of 10 RCTs of advanced therapies (TNF antagonists: infliximab, adalimumab, golimumab; vedolizumab; ustekinumab; tofacitinib) in patients with moderate-to-severe UC, we compared the efficacy (induction of clinical remission, endoscopic improvement, endoscopic remission, and symptomatic remission) and safety (serious adverse events [SAEs] and infections) of induction therapy in older (≥ 60y) vs younger adults (&lt; 60y). Modified Poisson regression was used to estimate the ratio of risk ratios (RRR) of treatment effects by age, adjusting for baseline endoscopic severity, disease duration, disease extent, prior biologic exposure, C-reactive protein, albumin, hemoglobin, concomitant corticosteroid use, and clustering effect by studies.</p> Results <p>Among 6192 patients (mean age 39.6&#xa0;years, 41% female), 634 (10.2%) were aged ≥ 60&#xa0;years. Efficacy of all advanced therapies over placebo was similar in older vs younger adults, with no significant treatment effect modification (induction of clinical remission: TNF antagonists, RRR of older vs younger adults, 0.94 [95% CI, 0.41–2.15]; non-TNF-targeting agents, RRR, 1.26 [0.60–2.62]). However, older adults were significantly more likely to experience infections with advanced therapies vs placebo, compared with younger adults (TNF antagonists, RRR, 1.52 [1.12–2.05]; non-TNF-targeting agents, RRR, 2.04 [1.45–2.87]).</p> Conclusion <p>In patients with moderate-to-severe UC, older age did not modify the magnitude of efficacy but was associated with higher magnitude of infection during induction with advanced therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Dhruv Ahuja,
  • Jaeyoun Choi,
  • Guangyong Zou,
  • Shane W. Goodwin,
  • Vipul Jairath,
  • Siddharth Singh

摘要

Background and Aims

We evaluated whether age modifies treatment efficacy and safety of advanced therapies in patients with moderate-to-severe ulcerative colitis (UC).

Methods

Through an individual patient-level data (IPD) meta-analysis of 10 RCTs of advanced therapies (TNF antagonists: infliximab, adalimumab, golimumab; vedolizumab; ustekinumab; tofacitinib) in patients with moderate-to-severe UC, we compared the efficacy (induction of clinical remission, endoscopic improvement, endoscopic remission, and symptomatic remission) and safety (serious adverse events [SAEs] and infections) of induction therapy in older (≥ 60y) vs younger adults (< 60y). Modified Poisson regression was used to estimate the ratio of risk ratios (RRR) of treatment effects by age, adjusting for baseline endoscopic severity, disease duration, disease extent, prior biologic exposure, C-reactive protein, albumin, hemoglobin, concomitant corticosteroid use, and clustering effect by studies.

Results

Among 6192 patients (mean age 39.6 years, 41% female), 634 (10.2%) were aged ≥ 60 years. Efficacy of all advanced therapies over placebo was similar in older vs younger adults, with no significant treatment effect modification (induction of clinical remission: TNF antagonists, RRR of older vs younger adults, 0.94 [95% CI, 0.41–2.15]; non-TNF-targeting agents, RRR, 1.26 [0.60–2.62]). However, older adults were significantly more likely to experience infections with advanced therapies vs placebo, compared with younger adults (TNF antagonists, RRR, 1.52 [1.12–2.05]; non-TNF-targeting agents, RRR, 2.04 [1.45–2.87]).

Conclusion

In patients with moderate-to-severe UC, older age did not modify the magnitude of efficacy but was associated with higher magnitude of infection during induction with advanced therapies.